Precigen (PGEN) Competitors $2.95 +0.01 (+0.34%) Closing price 04:00 PM EasternExtended Trading$2.94 -0.02 (-0.51%) As of 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PGEN vs. AGIO, IRON, DNLI, HRMY, IDYA, MESO, ADPT, ANIP, CGON, and VCELShould you be buying Precigen stock or one of its competitors? The main competitors of Precigen include Agios Pharmaceuticals (AGIO), Disc Medicine (IRON), Denali Therapeutics (DNLI), Harmony Biosciences (HRMY), IDEAYA Biosciences (IDYA), Mesoblast (MESO), Adaptive Biotechnologies (ADPT), ANI Pharmaceuticals (ANIP), CG Oncology (CGON), and Vericel (VCEL). These companies are all part of the "pharmaceutical products" industry. Precigen vs. Its Competitors Agios Pharmaceuticals Disc Medicine Denali Therapeutics Harmony Biosciences IDEAYA Biosciences Mesoblast Adaptive Biotechnologies ANI Pharmaceuticals CG Oncology Vericel Agios Pharmaceuticals (NASDAQ:AGIO) and Precigen (NASDAQ:PGEN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation. Do analysts recommend AGIO or PGEN? Agios Pharmaceuticals currently has a consensus price target of $56.33, indicating a potential upside of 50.42%. Precigen has a consensus price target of $6.00, indicating a potential upside of 103.39%. Given Precigen's higher probable upside, analysts clearly believe Precigen is more favorable than Agios Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agios Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75Precigen 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has more volatility & risk, AGIO or PGEN? Agios Pharmaceuticals has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, Precigen has a beta of 1.87, meaning that its stock price is 87% more volatile than the S&P 500. Is AGIO or PGEN more profitable? Agios Pharmaceuticals has a net margin of 1,590.42% compared to Precigen's net margin of -2,868.66%. Agios Pharmaceuticals' return on equity of -3.49% beat Precigen's return on equity.Company Net Margins Return on Equity Return on Assets Agios Pharmaceuticals1,590.42% -3.49% -3.23% Precigen -2,868.66%-842.83%-78.98% Which has stronger valuation & earnings, AGIO or PGEN? Agios Pharmaceuticals has higher revenue and earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAgios Pharmaceuticals$40.88M53.23$673.72M$11.003.40Precigen$4.34M202.54-$126.24M-$0.42-7.02 Does the media prefer AGIO or PGEN? In the previous week, Precigen had 29 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 36 mentions for Precigen and 7 mentions for Agios Pharmaceuticals. Agios Pharmaceuticals' average media sentiment score of 0.65 beat Precigen's score of 0.62 indicating that Agios Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Precigen 6 Very Positive mention(s) 8 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Do institutionals and insiders believe in AGIO or PGEN? 33.5% of Precigen shares are owned by institutional investors. 4.3% of Agios Pharmaceuticals shares are owned by company insiders. Comparatively, 47.1% of Precigen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryAgios Pharmaceuticals beats Precigen on 9 of the 15 factors compared between the two stocks. Get Precigen News Delivered to You Automatically Sign up to receive the latest news and ratings for PGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PGEN vs. The Competition Export to ExcelMetricPrecigenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$879.02M$3.12B$5.70B$9.79BDividend YieldN/A2.21%3.77%4.10%P/E Ratio-7.0220.7930.8625.27Price / Sales202.54232.09403.8888.61Price / CashN/A41.5625.2228.45Price / Book22.699.749.516.00Net Income-$126.24M-$54.74M$3.26B$265.34M7 Day Performance69.54%8.13%4.50%2.79%1 Month Performance67.61%7.74%5.22%1.51%1 Year Performance170.64%18.08%31.92%25.40% Precigen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PGENPrecigen3.8537 of 5 stars$2.95+0.3%$6.00+103.4%+169.7%$879.02M$4.34M-7.02190News CoverageEarnings ReportAnalyst UpgradeAnalyst RevisionHigh Trading VolumeAGIOAgios Pharmaceuticals4.281 of 5 stars$35.10-1.8%$56.33+60.5%-17.8%$2.04B$40.88M3.19390IRONDisc Medicine3.5065 of 5 stars$58.59+1.0%$95.73+63.4%+24.9%$2.03BN/A-13.1130News CoverageAnalyst ForecastInsider TradeDNLIDenali Therapeutics4.141 of 5 stars$13.91-0.3%$33.85+143.3%-36.1%$2.02B$330.53M-5.21430Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionHRMYHarmony Biosciences4.5129 of 5 stars$34.80+1.8%$51.00+46.6%+5.5%$2.00B$714.73M11.23200IDYAIDEAYA Biosciences4.4636 of 5 stars$22.84-1.1%$48.09+110.6%-35.6%$2.00B$7M-6.0380MESOMesoblast1.913 of 5 stars$14.70-2.2%$18.00+22.4%+144.0%$1.88B$5.90M0.0080ADPTAdaptive Biotechnologies2.4408 of 5 stars$12.15-0.4%$12.38+1.9%+170.0%$1.85B$178.96M-14.82790ANIPANI Pharmaceuticals3.1184 of 5 stars$84.88+4.2%$84.75-0.2%+45.7%$1.84B$674.07M-110.23600Analyst UpgradeHigh Trading VolumeCGONCG Oncology1.3559 of 5 stars$23.94-3.7%$55.30+131.0%-24.9%$1.82B$1.14M-13.5361VCELVericel2.4606 of 5 stars$35.43-2.2%$60.33+70.3%-21.6%$1.79B$249.12M295.27300News CoveragePositive News Related Companies and Tools Related Companies AGIO Competitors IRON Competitors DNLI Competitors HRMY Competitors IDYA Competitors MESO Competitors ADPT Competitors ANIP Competitors CGON Competitors VCEL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PGEN) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredTrump’s SHOCKING Plan to Create MASSIVE Wealth for AmericansJames Altucher says Donald Trump just made a move so surprising, it could go down as the most lucrative presid...Paradigm Press | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredAmericans are rushing into gold (but not billionaires!)Billionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precigen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precigen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access